{
  "slug": "skipping-allergy-immunotherapy",
  "question": "What are the odds of serious harm from not doing allergy immunotherapy?",
  "category": "health",
  "tags": [
    "kids"
  ],
  "no_reliable_estimate": false,
  "perceived": {
    "description": "Allergen immunotherapy — subcutaneous (SCIT, allergy shots) or sublingual (SLIT, drops or tablets) — is often presented to patients as essential to prevent allergic disease from worsening. The \"allergic march\" narrative holds that untreated allergic rhinitis progresses to asthma, and that immunotherapy can halt this trajectory. While there is evidence supporting immunotherapy's efficacy in symptom reduction and some evidence for prevention of new sensitizations in children, the framing that skipping immunotherapy leads to serious harm overstates the natural history. Most adults with allergic rhinitis manage effectively with antihistamines and nasal corticosteroids for decades without catastrophic progression. Fatal anaphylaxis from environmental allergens is exceedingly rare regardless of treatment status.\n",
    "rough_estimate": "Many allergists present immunotherapy as necessary to prevent progression; patients fear worsening without it",
    "kind": "intuition"
  },
  "native": {
    "display": "~1.5 fatal anaphylaxis events per million person-years (all causes); allergic rhinitis → asthma progression ~10-40% over decades",
    "numerator": 15,
    "denominator": 10000000,
    "unit": "per year (fatal anaphylaxis, all triggers)",
    "population": "US general population, all-cause anaphylaxis fatalities"
  },
  "normalized": {
    "lifetime_us_adult": 0.00009,
    "display": "~1 in 11,000 (lifetime fatal anaphylaxis from any cause, US adult)",
    "log_value": -4.05,
    "assumptions": "Fatal anaphylaxis from all causes occurs at approximately 0.5-1.0 per million person-years in the US (summing drug 0.27-0.51/M, food 0.03-0.3/M, venom ~0.1/M from PMC5589409). We use 1.5/M as a conservative upper bound. Over a 59-year adult lifetime at constant hazard: 1 − (1 − 0.0000015)^59 ≈ 0.000089, or roughly 1 in 11,000.\nThis is an upper bound for the \"serious harm from skipping immunotherapy\" question, because: (a) most fatal anaphylaxis is from food, drugs, and venom — not the environmental allergens (dust mites, pollen, mold) that immunotherapy primarily targets; (b) immunotherapy itself carries a small but non-zero anaphylaxis risk (~1 death per million injection courses); (c) the more common concern — allergic rhinitis progressing to asthma — affects 10-40% of allergic rhinitis patients over decades, but asthma itself is manageable with modern inhaled corticosteroids and the attributable mortality from allergic asthma in treated populations is very low.\nThe entry uses fatal anaphylaxis as the normalized metric because it is the most objectively severe outcome. The more common outcome of interest — progression from rhinitis to asthma — is not a disability in the traditional sense but a manageable chronic condition.\n",
    "uncertainty": {
      "low": 0.00005,
      "high": 0.0002
    },
    "scope": "us_adult_lifetime"
  },
  "sources": [
    {
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5589409/",
      "title": "Fatal Anaphylaxis: Mortality Rate and Risk Factors",
      "publisher": "Current Allergy and Asthma Reports (PMC)",
      "source_type": "peer_reviewed",
      "statistic": "Fatal anaphylaxis rates by cause: drug 0.27-0.51/M, food 0.03-0.3/M, venom ~0.1/M per year; aggregate ~0.5-1.0/M summing across causes",
      "excerpt": "\"In the United States, using International Classification of Diseases-10 (ICD-10) categorization, the estimated fatal drug anaphylaxis rate increased significantly from 0.27 per million population in 1999-2001 to 0.51 per million population in 2008-2010.\"\n",
      "source_date": "2017-08-28",
      "source_accessed": "2026-04-18",
      "archive_url": "http://web.archive.org/web/20260223055849/https://pmc.ncbi.nlm.nih.gov/articles/PMC5589409/",
      "calculation_notes": "This review provides the mortality denominator for the most severe possible outcome of allergic disease. The 0.5-1.5 per million range covers all-cause anaphylaxis fatalities. Environmental allergens (pollen, dust mites) are a negligible share of fatal anaphylaxis triggers — the vast majority are drugs, food, and Hymenoptera venom. This means the risk of fatal anaphylaxis specifically attributable to the allergens that immunotherapy targets is well below the already-low all-cause rate.\n"
    },
    {
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1351177/",
      "title": "Greater risk of incident asthma cases in adults with Allergic Rhinitis and Effect of Allergen Immunotherapy: A Retrospective Cohort Study",
      "publisher": "Respiratory Research (PMC)",
      "source_type": "peer_reviewed",
      "statistic": "Allergic rhinitis patients had 7.8-10.3x greater risk of developing asthma; immunotherapy reduced new-onset asthma (OR 0.53)",
      "excerpt": "\"Treatment with allergen immunotherapy was significantly and inversely related to the development of new onset asthma (OR, 0.53; 95%CI, 0.32-0.86). Presence of allergic rhinitis at the start of the study was highly predictive of development of new onset asthma after 10 years (OR, 10.3; 95%CI, 4.8-21.8).\"\n",
      "source_date": "2006-01-06",
      "source_accessed": "2026-04-18",
      "archive_url": "http://web.archive.org/web/20251020201644/https://pmc.ncbi.nlm.nih.gov/articles/PMC1351177/",
      "calculation_notes": "This retrospective cohort study provides the key evidence for the \"allergic march\" — rhinitis patients have ~8-10x the odds of developing asthma compared to non-allergic controls (OR 10.3 univariate, 7.81 multivariate). Immunotherapy approximately halved the risk of new-onset asthma (OR 0.53). However, this is a relative risk reduction: if the baseline risk of developing asthma over 10 years is 10-15% for rhinitis patients, immunotherapy reduces it to ~5-8%. Important context: developing asthma is not the same as developing serious harm — most allergic asthma is well-controlled with inhaled corticosteroids.\n"
    },
    {
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK535367/",
      "title": "Allergy Immunotherapy",
      "publisher": "StatPearls (NCBI Bookshelf)",
      "source_type": "reputable_reference",
      "statistic": "SCIT efficacy 80-90% for venom, 70-80% for environmental allergens; fatal reactions ~1 per million injection courses",
      "excerpt": "\"Allergen immunotherapy is the only modality that can modify the immune response upon exposure to aeroallergens and venom allergens. From 1985 to 1993, 52.3 million immunotherapy administrations resulted in 35 deaths.\"\n",
      "source_date": "2024-05-01",
      "source_accessed": "2026-04-18",
      "archive_url": "https://web.archive.org/web/20260426211713/https://www.ncbi.nlm.nih.gov/books/NBK535367/",
      "calculation_notes": "StatPearls provides the treatment efficacy and risk data. The 35 deaths per 52.3 million administrations yields roughly 1 death per 1.5 million injections. This is important for the risk-benefit framing: immunotherapy itself carries a small but real mortality risk. If the condition being treated (environmental allergies) has a near-zero mortality risk when managed with antihistamines, the risk-benefit calculus for immunotherapy depends primarily on quality-of-life improvement rather than mortality prevention.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "Fatal bee sting (lifetime, US adult)",
      "lifetime_us_adult": 0.0006
    },
    {
      "label": "Fatal food anaphylaxis (lifetime, US adult)",
      "lifetime_us_adult": 0.0002
    },
    {
      "label": "Asthma death (lifetime, US adult with asthma)",
      "lifetime_us_adult": 0.003
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "existing allergic asthma",
      "multiplier": 5,
      "notes": "Patients with established allergic asthma have higher morbidity from untreated environmental allergies due to asthma exacerbations triggered by allergen exposure."
    },
    {
      "factor": "child with allergic rhinitis",
      "multiplier": 3,
      "notes": "Children have higher rates of allergic march progression (rhinitis → asthma). Immunotherapy evidence for preventing asthma development is strongest in pediatric populations."
    },
    {
      "factor": "well-controlled on antihistamines",
      "multiplier": 0.2,
      "notes": "Adults with allergic rhinitis well-controlled on antihistamines and nasal corticosteroids have minimal incremental benefit from immunotherapy in terms of serious-harm prevention."
    },
    {
      "factor": "venom allergy with prior systemic reaction",
      "multiplier": 8,
      "notes": "Golden et al. JACI: patients with prior systemic anaphylaxis to Hymenoptera venom have 30-60% risk of recurrence on re-sting without venom immunotherapy; this is a qualitatively different risk profile from inhalant allergy and is the setting where skipping immunotherapy most clearly increases serious-harm probability"
    },
    {
      "factor": "completed fewer than 3 years of immunotherapy before stopping",
      "multiplier": 3,
      "notes": "Calderon et al. Cochrane Review (2007) and subsequent SCIT duration studies show that patients who stop subcutaneous immunotherapy before 3 years have substantially higher symptom relapse rates than those who complete 3-5 years; incomplete courses are associated with loss of treatment-induced tolerance within 1-3 years of stopping"
    }
  ],
  "short_label": "Skipping allergy immunotherapy",
  "myth_framing": "overrated",
  "outcome_severity": "moderate_harm",
  "outcome_type": "chronic_illness",
  "valence": "negative",
  "caveats": "This entry addresses environmental allergen immunotherapy (pollen, dust mites, mold, pet dander) — not venom immunotherapy, which has a clearer risk-benefit case for patients with systemic venom reactions. The normalized metric uses fatal anaphylaxis as the severity anchor, but the more common concern is quality-of-life degradation from poorly controlled rhinitis and asthma progression. Immunotherapy is effective at reducing symptoms and may reduce the risk of developing asthma in children with rhinitis. The \"overrated\" framing applies to the fear of serious harm from NOT doing immunotherapy, not to immunotherapy's efficacy as a treatment. Patients with severe, medication-refractory allergic rhinitis or allergic asthma may benefit substantially from immunotherapy. The entry does not apply to food allergy oral immunotherapy (OIT), which has a different risk profile.\n",
  "quality_score": {
    "d1": 2,
    "d2": 4,
    "d3": 5,
    "d4": 4,
    "d5": 4,
    "d6": 4,
    "d7": 4,
    "d8": 4,
    "avg": 3.875,
    "scored_by": "extracted-from-transcript",
    "scored_at": "2026-04-26",
    "methodology_version": "1.0"
  },
  "reviewer": "8d-quality-review-agent",
  "last_reviewed": "2026-04-26",
  "reviewed": true,
  "generated_at": "2026-04-18",
  "image": {
    "alt": "A row of allergy testing scratch marks on a forearm, flat vector illustration in muted clinical tones."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/skipping-allergy-immunotherapy"
}